RxDoctor Payments Data

Hyung Yeo, MD

Child & Adolescent Psychiatry · Southampton, PANPI 1902943178

Payments from drug & device makers

$590in general payments, 2019–2025

Across 27 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$197
  • Lundbeck LLC$136
  • E.r. Squibb & Sons, L.L.C.$87
  • Otsuka America Pharmaceutical, Inc.$37
  • OWP Pharmaceuticals, Inc.$31
  • Ironshore Pharmaceuticals Inc.$30
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$588100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$590 in reported general payments places this provider in the 65th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.

See all child & adolescent psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$12,809
Medicare patients
32
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole14$38,842
VraylarCariprazine Hcl28$37,547
Lurasidone Hcl34$7,494
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine147$3,267
Trazodone Hcl258$2,716
Buspirone Hcl139$1,438
Methylphenidate ErMethylphenidate Hcl11$1,335
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine52$1,335
Bupropion XlBupropion Hcl108$1,268
Ziprasidone Hcl21$1,173
Clonazepam185$1,076
Olanzapine42$1,065
Bupropion Hcl SrBupropion Hcl89$1,009
Duloxetine Hcl104$942
Sertraline Hcl110$914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$37$38,84214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.

Other child & adolescent psychiatry in Southampton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →